Marcain Polyamp Steripack (Bupivacaine Hydrochloride)

Bupivacaine blocks voltage‑gated sodium channels on nerve membranes, preventing sodium influx that is essential for depolarisation. By inhibiting nerve impulse generation and propagation, it temporarily stops the transmission of pain signals from the site of injection to the brain.

The specific dose of Marcain Polyamp Steripack is determined by the prescribing clinician based on the procedure, patient weight, and site of administration. Healthcare professionals calculate the appropriate volume to stay within recommended maximum limits.

Safety data for bupivacaine in pregnancy and lactation are limited. Use is generally reserved for situations where the benefit to the mother outweighs potential risks to the fetus or infant, and the decision should be made by a qualified obstetrician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Bupivacaine provides a longer duration of action compared with agents such as lidocaine or mepivacaine, making it suitable for procedures requiring extended anesthesia. However, its higher potency also demands careful dosing and monitoring for cardiotoxicity, especially when combined with other agents.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discoloured or contains particulate matter.

Marcain Polyamp Steripack is administered by infiltration or regional nerve block using aseptic technique. The sterile solution is injected directly into the tissue or around the target nerve under the guidance of a qualified healthcare professional.

Serious risks include cardiac arrhythmias, severe hypotension, seizures, and rare allergic reactions such as anaphylaxis. These events are more likely with high plasma concentrations, inadvertent intravascular injection, or when combined with other cardiotoxic drugs.

Patients with known hypersensitivity to amide‑type local anesthetics, severe cardiac conduction disorders, or those receiving class I antiarrhythmic agents should avoid bupivacaine. Clinicians should also exercise caution in patients with compromised hepatic function or those on medications that lower the seizure threshold.